Ceek Women’s Health and Lupin Sign a Marketing Agreement

Ceek Women’s Health (Ceek), the women-led, groundbreaking medical device company and Lupin Pharmaceuticals Inc., the US sales and marketing subsidiary of Lupin Limited (Lupin), announced an agreement to add the Nella women’s health products to Lupin’s promotional offering in the United States.

Under the promotional arrangement, Lupin’s sales representatives will detail and demonstrate Ceek products including the Nella NuSpec (the Smarter Reusable Vaginal Speculum), VuSleeve, and VuLight products, alongside Lupin Women’s Health flagship product, Solosec® (secnidazole) 2g oral granules indicated for the treatment of bacterial vaginosis (BV), a common vaginal infection in adult women.16  

Offering the first meaningful update to the vaginal speculum in nearly 150 years, the Nella NuSpec which will launch shortly, is the result of extensive prototyping and research to change the patient experience during gynecological exams. The VuSleeve and the VuLight are accessories to the speculum designed to provide easy visualization and access to the cervix.

The Nella products are designed to improve the quality of care for all women as well as in specific segments, including adolescents, transgender patients, rape or trauma patients, post-menopausal women, and cancer survivors. Ceek has been the recipient of three prestigious product design awards including the 2020 Red Dot Award, the 2020 iF Award, and the 2019 Core77 Notable Design Award.

“We have dedicated ourselves to pioneering quality women’s health products that are transforming gynecological care and improving the exam experience for all patients,” said Fahti Khosrowshahi, CEO and Founder of Ceek. “We are very proud to partner with Lupin to introduce our products to their network of obstetricians and gynecologists, allowing us to offer more options to a greater range of patients than previously thought possible.” Jon Stelzmiller, President – Specialty Lupin Pharmaceuticals, Inc. added, “We share the same sentiment and commitment to women’s health as Ceek, making it that much more meaningful as we add these ground-breaking and innovative offerings to our providers and patients.”

Lupin Women’s Health flagship product, Solosec will also be a part of the offering. Solosec® 2g oral granules, a single-dose therapy for bacterial vaginosis (BV), the most common vaginal infection in the U.S., affecting more than 20 million women between the ages of 14 and 49 annually.

Solosec® was designed to be easy to take for patients with BV, with one oral dose containing a full course of treatment.[i] After one dose, Solosec® continues to treat BV for four days without any alcohol restriction – in vitro drug alcohol studies show Solosec® does not inhibit the enzyme that metabolizes alcohol.8 In a survey answered by 85 women who completed Solosec®  treatment, 9 out of 10 were satisfied, very satisfied, or extremely satisfied with the result of their Solosec® treatment, and would recommend to a friend with BV that they speak to their doctor about Solosec®.[ii]

To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at  1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Full Prescribing Information Here.


[i] SOLOSEC® [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2017.

[ii] Data on file. Experience Program: Post Treatment Patient Survey data (May 2019-Sep 2019). Prepared September 2019. (LPSO-23506). Lupin Pharmaceuticals, Inc.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy